Drug: soluble ferric pyrophosphate
0, 5, 10, 12, 15 and possibly 20mcg iron/dl of dialysate

Inclusion Criteria:

1. Adult subject ≥18 years of age undergoing chronic hemodialysis for end-stage renal disease (ESRD) three times a week
2. Hemoglobin values on two successive screening/baseline measures immediately prior to the start of the study of 10.1 to 11.5 g/dL
3. TSAT values that average 20% or more, but not exceeding 35% prior to dialysis measured during the screening period
4. Ferritin values that average 200 to 800 μg/L measured during the screening period
5. Subject has no hospitalizations in previous three months for a significant illness related to a renal or dialysis problem except for vascular access surgery
6. Subject has an adequate dialyzer blood flow rate that is acceptable to the Principal Investigator

Exclusion Criteria:

1. Hemoglobin values on two successive baseline/screening measurements that average ≥11.6g/dL
2. Subject with a current malignancy involving sites other than skin
3. Subject with a history of drug or alcohol abuse within the last six months
4. Subject believed to be unable to complete the entire study (e.g., due to a concurrent disease,life expectancy of less than a year)
5. Subject who the Principal Investigator considers will be placed at increased risk by the study procedures
6. Subject requiring hemodialysis more than 3 times per week on a regular basis.
7. Subject who is unable to discontinue oral iron or intravenous iron supplements for the duration of the study.
8. Subject who is pregnant
9. Subject considered incompetent to give an informed consent
10. Subject with a positive test for Hepatitis B Surface Antigen within the past 30 days or during screening
11. Subject with known HIV infection (If this is not known, no HIV testing will be performed.)
12. Subject with cirrhosis of the liver based on histological criteria or clinical criteria (presence of ascites, esophageal varices, spider nevi, or history of hepatic encephalopathy). Subject with hepatitis C, in the absence of cirrhosis, is not excluded from participation in the study if ALT and AST levels are below 2 times the upper limit of normal consistently during the 2 months preceding enrollment
13. Subject with active tuberculosis, fungal, viral, or parasitic infections
14. Subject with active bacterial infections requiring antibiotic therapy
15. Subject with a marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval ≥450 milliseconds (ms)
16. Subject with a history of additional risk factors for Torsades de Pointe ( e.g. heart failure,hypokalemia, family history of Long QT Syndrome)
17. Subject using concomitant medications known to prolong QT/QTc interval (See Appendix I)
18. Subject receiving more than 30,000 units or 60 micrograms of erythropoietin (Epogen®,Procrit®, Aranesp®) per week
19. Subject has participated in another clinical trial within 30 days of signing Informed Consent